Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg H H, De Vinci C, Viza D
Immunodiagnosis and Immunotherapy Unit, Ospedale S. Orsola-Malpighi, Bologna, Italy.
Biotherapy. 1996;9(1-3):41-7. doi: 10.1007/BF02628655.
Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF. The number of lymphocytes, CD4 and CD8 subsets were followed and showed no statistically significant variations. In 11/25 patients the number of lymphocytes increased, whilst in 11/25 decreased; similarly an increase of the CD4 lymphocytes was observed in 11/25 patients and of the CD8 lymphocytes in 15/25. Clinical improvement or a stabilized clinical condition was noticed in 20/25 patients, whilst a deterioration was seen in 5/25. In 12/14 anergic patients, daily TF administration restored delayed type hypersensitivity to recall antigens within 60 days. These preliminary observations suggest that oral HIV-specific TF administration, in association with antiviral drugs, is well tolerated and seems beneficial to AIDS patients, thus warranting further investigation.
25名处于不同阶段（美国疾病控制与预防中心II、III和IV期）的HIV-1感染患者口服HIV-1特异性转移因子（TF），治疗时间从60天至1870天不等。所有患者在接受TF治疗的同时还接受抗病毒治疗。对淋巴细胞、CD4和CD8亚群的数量进行跟踪，结果显示无统计学上的显著变化。25名患者中有11名淋巴细胞数量增加，11名淋巴细胞数量减少；同样，25名患者中有11名CD4淋巴细胞数量增加，15名CD8淋巴细胞数量增加。25名患者中有20名临床症状改善或病情稳定，5名病情恶化。在14名无反应性患者中的12名中，每日给予TF可在60天内恢复对回忆抗原的迟发型超敏反应。这些初步观察结果表明，与抗病毒药物联合使用时，口服HIV特异性TF耐受性良好，似乎对艾滋病患者有益，因此值得进一步研究。
